We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Drug Company Buyout to Boost Development of Liver Disease Drugs

By LabMedica International staff writers
Posted on 20 Apr 2016
A strategic buyout will broaden the role of an American pharmaceutical research and manufacturing company in the area of liver diseases.
 
 
 
The biopharmaceutical company Gilead Sciences (Foster City, CA, USA) has announced the purchase of Nimbus Apollo Inc., a subsidiary of Nimbus Therapeutics LLC (Cambridge, MA, USA). More...
Gilead is set to pay 400 million USD for Nimbus Apollo, and the parent company could receive up to another 800 million USD, if Nimbus Apollo's drug development program meets certain milestones in testing results and medicine approval and sales.
 
 
 
Implementation of the agreement will give Gilead access to the experimental drug NDI-010976, which is being tested for the treatment of non-alcoholic steatohepatitis, known by the acronym NASH. This disorder causes inflammation, cell damage, progressive scarring, and cirrhosis of the liver. An estimated 15 million Americans suffer from NASH.
 
 
 
In February 2016, the drug NDI-010976 was awarded [US] Food and Drug Administration "fast-track" designation, which speeds up regulatory review and approval. The drug blocks two forms of the enzyme acetyl CoA carboxylase (ACC), which is involved in cellular fatty acid metabolism.
 
 
 
Dr. Norbert Bischofberger, CSO at Gilead, said, "The acquisition will complement and further strengthen Gilead's ongoing efforts to address unmet needs in NASH."
 
 
 
In addition to the acquisition of NDI-010976, the purchase brings to Gilead Nimbus' breakthrough computational chemistry platform that was designed to enable rapid discovery, design, and tweaking of potential medicinal compounds.
 
 
Related Links: 
 
 


 

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
HPV Test
Allplex HPV28 Detection
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.